-
-
-
-
-
-
-
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
-
-
-
-
-
-
-
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
-
-
-
-
-
-
-
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
-
-
-
-
-
-
-
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
-
-
-
-
-
-
-
Amgen's Repatha reduces heart attack risk by 25% in major study
-
-
-
-
-
-
-
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
-
-
-
-
-
-
-
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
-
1,167,583 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

